Skip to main content

Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis



Stroke, an acute cerebrovascular event, is a leading cause of disability, placing a significant psycho-socioeconomic burden worldwide. The adaptation and reorganization process following any neuronal damage is regarded as neuroplasticity. Among many factors believed to attribute to this process, Brain-derived Neurotrophic Factor (BDNF) is a neurotrophin coordinating neuroplasticity after various neurological disorders such as stroke.


We conducted a systematic search in the main electronic medical databases in January 2021. Primarily we want to compare BDNF levels between patients with stroke and healthy controls (HC). Additional aims included investigation of (1) longitudinal changes in the BDNF levels post-stroke, (2) effects of physical training, (3) repeated transcranial magnetic stimulation (rTMS), and presence of depression on BDNF levels in patients with stroke.


Among 6243 reviewed records from PubMed, Web of Science, and Scopus, 62 studies were eligible for inclusion in our systematic review. Subjects with stroke, n = 1856, showed lower BDNF levels compared to HC, n = 1191 (SMD [95%CI] = − 1.04 [− 1.49 to − 0.58]). No significant difference was detected in the level of BDNF through time points past stroke. BDNF levels were lower in the patients with depression compared to non-depressed subjects (SMD [95%CI] = − 0.60 [− 1.10 to − 0.10]). Physical training had an immediate positive effect on the BDNF levels and not statistically significant effect in the long term; SMD [95%CI] = 0.49 [0.09 to 0.88]) and SMD [95%CI] = 0.02 [− 0.43 to 0.47]). Lastly, rTMS showed no effect on the level of BDNF with 0.00 SMD.


Our study confirms that stroke significantly decreases the level of BDNF in various domains such as cognition, affect, and motor function. As BDNF is the major representative of neuroplasticity within nervous system, it is believed that stroke has a significant impact on the CNS regeneration, which is permanent if left untreated. This effect is intensified with coexisting conditions such as depression which further decrease the BDNF level but the net impact yet needs to be discovered. We also conclude that exercise and some interventions such as different medications could effectively reverse the damage but further studies are crucial to reach the exact modality and dosage for their optimal effect.


Beyond 13 million people are affected by stroke annually, which is among the leading causes of incapacity and mortality, placing a significant psycho-socio economic burden worldwide [1]. Through the advent of medical techniques, mortality rates following stroke have dropped remarkably, leading to higher disability-adjusted life years (DALY) [2]. Approximately 26% of patients with stroke (PwS) will face levels of dependency in their daily activities up to six months after the stroke onset [3]. However, the motor function is not the mere focus of disabilities among PwS; patients’ cognitive profile and affect are also altered by stroke [4, 5].

Acute stroke is referred to the acute onset of focal neurological findings in a vascular territory. There are two main types of stroke, following a vascular occlusion resulting in an infarct, regarded as ischemic stroke (85%), or caused by a sudden burst of a blood vessel, regarded as hemorrhagic stroke (15%). In response to this cerebrovascular event, CNS uses an ability to adapt and reorganize the damage known as “Neuroplasticity”. A group of signaling molecules known as neurotrophins play essential roles in synaptic plasticity, neurogenesis and survival regulations in neural cells [6,7,8]. In particular, many studies have investigated Brain-Derived Neurotrophic Factor (BDNF) as a member of the neurotrophins family for its role in the nervous system [9,10,11]. Extensive evidence demonstrated some associations between BDNF level and various neurological disorders; for instance, low concentrations of BDNF has been reported in neurodegenerative and neuropsychiatric disorders such as Alzheimer’s disease, Parkinson’s disease, depression, autism spectrum disorders, and post-traumatic stress disorder [9,10,11,12].

Keen interest has been raised to find the relationship between the altered level of BDNF and stroke; studies hypothesize that BDNF level is correlated with the size of the stroke legion, cognitive profile, and functional outcome [13,14,15]. Based on the substantial impact of stroke, a systematic review and meta-analysis are essential to address the precise association of circulating BDNF in PwS in various conditions.

Materials and method

Literature search and selection criteria

We conducted a comprehensive systematic search by using the keywords “stroke” OR “ischemic stroke” OR “hemorrhagic stroke” OR “Cerebrovascular Accident” OR “Brain Vascular Accident” AND “Brain-Derived Neurotrophic Factor” OR “BDNF” on PubMed, Web of Science and Scopus in January 2021. Original articles were included by the following criteria; (1) a study measuring serum or plasma levels of BDNF in PwS. Studies (a) with animal subjects, (b) review or meta-analysis studies, (c) genetic investigation were excluded from the study (d) using other measuring methods rather than ELISA, like western blot, mass spectrometry or immunohistochemistry.

Additionally, the reference list and citations of all included articles were checked to find potential eligible articles, resulting in 5 eligible articles. We updated our search, using the exact keywords, on August 7th 2021, which resulted in the inclusion of one study [16]. Finally, a total number of 62 articles were entered into our systematic review (Fig. 1).

Fig. 1
figure 1

PRISMA flow diagram

Data extraction

The following data were extracted from each included publication; the name of the first author, year of publication, location of study (country), type of specimen (serum, plasma or CSF), number of subjects in each study group, demographic characteristics (i.e., age and gender) of both groups, stroke type (ischemic or hemorrhagic), stroke site, patients’ score for National Institutes of Health Stroke Scale (NIHSS), post-stroke duration at the time of sample collection, mean and standard deviation (SD) of the peripheral BDNF levels, and the assay used for BDNF measurement.

Two independent researchers extracted data from each manuscript, and the mismatch was discussed and resolved afterwards. In the case of figure illustration, the data were interpreted from the figure using an online interpreter [17]. The corresponding/first authors were contacted and invited to share their results if the two prior approaches were unsuccessful. An excel spreadsheet was made from the relevant data and is available on request. Characteristics of the included studies is illustrated in Table 1.

Table 1 Characteristics of the included studies


Quality assessment

Two authors performed the methodological quality assessment independently to evaluate each included study's risk of bias and applicability by QUADAS-2 tool [18]. This tool is designed to assess the risk of bias in four main domains, including patient selection, index test, reference standard and, flow and timing. Concerns regarding the applicability were also apprised in the first three domains. In each domain, there are three possible rankings; studies categorized as “high” represent the lowest quality with the highest risk of bias and concerns, while studies categorized as “low” indicate the highest quality with the lowest risk of bias and considerations. The “unclear” category was used for studies that reported insufficient data in each domain. Any disagreement was resolved by discussion or consultation with another author (Table 2 and Fig. 2).

Table 2 QUADAS
Fig. 2
figure 2

Proportion of risk of bias assessment by each domain

Quantitative analysis

All statistical analyses were performed using “meta” (version 4.17–0), “metafor” (version 2.4–0), and “dmetar” (version 0.0–9) packages, R (R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria) and STATA. A p-value of < 0.05 was considered statistically significant. 


We reported standardized mean difference (SMD) (Hedge's g) and 95% confidence interval (CI) for each between-group comparison. The SMD of \(\le\) 0.2, 0.2–0.8, and 0.8 \(\le\) represented small, moderate, and large effect sizes, respectively.

The Cochran’s Q test and the I2-index were used to investigate heterogeneity between studies. The I2-indices of \(\le\) 25%, 26–75%, and 75% ≤ represented low, moderate, and high degrees of heterogeneity, respectively [19]. Fixed effects models were applied if the results were homogeneous (I2 < 40% and p-value > 0.05), and random effect models according to the DerSimonian and Laird method [20] were used if these results were heterogeneous (I2 ≥ 40% or p-value ≤ 0.05) [21].

Our primary aim was to compare BDNF levels between PwS and healthy controls (HC). Additionally, we aimed to address (1) the longitudinal changes, (2) the effects of physical training, (3) repeated transcranial magnetic stimulation (rTMS), and (4) clinical diagnosis of post-stroke depression (PSD) on the circulating BDNF levels in PwS.

Within the groups undergoing additional analysis, some concerns existed in the physical training group. First, various training modalities were implemented, ranging from regular post-stroke physiotherapy sessions to different exercise protocols in addition to the variation in each session’s duration. Lastly, sample collection time varied between studies immediately after the session completion to weeks and months after the whole program was terminated.

To overcome this diversity and reach a reasonable grouping modality with maximum homogeneity, this is besides the heterogeneity and sensitivity analysis, we divided studies into two primary groups according to the time of sample collection, those who collected samples (1) immediately after the exercise (within 20 min to 24 h) and (2) with a time delay after the training was completed (within two weeks to a couple of months). The variety of the training protocols was also an interesting point throughout the studies. Thus we conducted a subgroup analysis between routine physiotherapy protocol and other exercise protocols. Although there were several specifications for the exercising routines like High-Intensity interval training (HIIT), we could not devote a specific subgroup for each due to the inadequate number of observations.

It is noteworthy that some of the included studies had applied two or more physical interventions, such as routine physiotherapy, aerobic exercise, and non-aerobic exercise, into different study groups, leading to more observational groups being included from the study. Similarly, many studies have reported both immediate and delayed levels so we could extract more than one observational groups from a single study. This clearly describes repeated study names in our meta-analysis results. Table 3 illustrates a description of the included studies in our physical training group in detail.

Table 3 PT protocols

We had no concerns about the categorization of the other additional group analysis.

Regression and sensitivity analysis

To further assess causes of heterogeneity, we conducted separate regression of mean age and mean NIHSS2 on SMD whenever the required data was available for a number ten or more studies. Moreover, for the meta-analyses including ten or more studies that had significant heterogeneity, we conducted sensitivity analysis to identify influential articles. We performed Leave-One-Out analysis by omitting one study each time and recalculating the effect size. We also applied the diagnostic procedure developed by Viechtbauer and Cheung [22] to detect influential cases and Baujat Plot [23] to investigate each study's effect on the effect size and heterogeneity.

Meta bias

We assessed publication bias by visual inspection of the degree of funnel plot asymmetry. Egger bias test [24] and Begg-Mazumdar Kendall's tau [25] were also performed to confirm the visual perception from the funnel plot objectively. A p-value < 0.1 was considered as evidence of publication bias.


Our initial database search revealed a total number of 6243 citations. We removed 2495 duplicate citations, and 3653 additional citations were excluded through title and abstract screening. We retrieved 95 articles for full-text screening, from which 29 studies were excluded for the following reasons: animal sample size, review article, duplicated articles from one same study, in vitro study, and reporting one single measure in one single study group at only one-time point. An additional number of 5 articles were removed during the data extraction because of: insufficient data despite author contact [22, 26], reporting BNGF instead of BDNF [23], unclear data from an extensive cohort study (Framingham [3]), reporting peripheral BDNF in association with another biomarker instead of pure measures [27].

Finally, a total number of 62 articles were entered into our systematic review. We could not enter 16 articles to any meta-analysis group for the following reasons; providing delta BDNF instead of exact measures [28], reporting peripheral BDNF as a proportion to the control group [29], the full text was not found. However the abstract was sufficient to extract the descriptive data [30], unsatisfactory data and irresponsive author (missing SD despite reporting the mean) [31], single study group with no comparison or specific grouping which did not fall into our meta-analysis categorizations [14, 32,33,34,35,36,37,38,39,40,41,42].

Serum BDNF levels in PwS vs. HC

Seventeen studies assessed the differences between serum BDNF levels in PwS (n = 1191) and HC (n = 1856) [13, 16, 43,44,45,46,47,48,49,50,51,52,53,54,55,56,57]. PwS had significantly lower serum BDNF levels than HC (SMD [95%CI] = − 1.02 [− 1.47 to − 0.57], p-value < 0.001, I2 = 96%, p-value < 0.001) (Fig. 3). No publication bias was detected (Fig. 4). Sensitivity analysis showed that Align et al. [58] and Chan et al. [54] were influential (Additional file 1: Fig. S1). After excluding these studies, the meta-analysis of the remaining fifteen studies showed significantly lower serum BDNF levels in PwS than HC as well (− 0.92 [− 1.35 to − 0.50], p-value < 0.001, I2 = 96%, p-value < 0.001). To further assess sources of heterogeneity, we performed meta-regression. The age partially explained the high heterogeneity (correlation coefficient = − 0.11, R2 = 62.81%, p-value = 0.000).

Fig. 3
figure 3

Forest HC stroke

Fig. 4
figure 4

Funnel HC stroke

Longitudinal investigation within stroke population

To address the pattern of serum BDNF level through the time of stroke onset, 23 studies longitudinally assessed their samples. A total number of 3678 patients were included in 39 observations. Time points for sample collection varied extremely between the studies. After the precise data extraction for the time of sample collection regarding the stroke onset, we grouped the observation into five general groups. (1) Observations which compared baseline measures to the first day of the stroke, baseline vs day one or acute that covered four observations and 202 participants [32, 39, 59, 60]; (2) Observations comparing the baseline measures to the peripheral level of BDNF within the first week of stroke onset (mostly 3–7 days) baseline vs week one or sub-acute, consisting of 14 observations and 1366 patients [32, 39, 42, 44, 54, 56, 59, 61,62,63,64,65,66,67]; (3) Observations investigating the difference between baseline levels of BDNF and day 30 or above, baseline vs. over one month or chronic, that included 11 observations and 1093 participants [16, 39, 43, 54, 56, 65,66,67,68,69]; (4) Comparison of the first day of the stroke to the first week after the onset, Day 1 vs Week 1 consisting three observations and 162 participants [32, 39, 59]; (5) Lastly the seven observations investigating the BDNF pattern, in 855 participants, within the first week of stroke and over the one months of affecting the patients [39, 54, 56, 65,66,67, 70].

Based on the high heterogeneity level detected with I2 (over 74%) in every group, we conducted a random effect model analysis separately for each above mentioned observational group. No significant difference were addressed in the SMD in any of the included groups. Nor any publication bias was found (Additional file 2: Fig. S2, Additional file 3: Fig. S3, Additional file 4: Fig. S4, Additional file 5: Fig. S5, Additional file 6: Fig. S6, Additional file 7: Fig. S7, Additional file 8: Fig. S8, Additional file 9: Fig. S9, Additional file 10: Fig. S10, Additional file 11: Fig. S11).

Effect of depression on serum BDNF levels in PwS

Six trials with 411 patients and 245 patients without depression compared serum BDNF between these two groups [43, 44, 71,72,73,74]. All the studies followed Diagnostic and Statistical Manual of Mental Disorders 4th version (DSM-IV) criteria to assess their sample for depression. Hamilton Depression Rating Scale (HDRS) was also used by four studies [43, 44, 73, 74]. While every included article assessed PSD, only two addressed the history of depression in their patients before the stroke [72, 73]. Patients with depression had significantly lower levels of BDNF than the participant in the non-depressed group (SMD [95%CI] = − 0.60 [− 1.10 to − 0.10], p-value < 0.001, I2 = 88%, p-value < 0.001) (Fig. 5). No publication bias was detected. Due to the low number of included studies, we could not conduct meta-regression or sensitivity analysis (Fig. 6).

Fig. 5
figure 5

Forest depression

Fig. 6
figure 6

Funnel depression

Effect of physical training on serum BDNF levels in PwS

Sixteen studies with 738 patients provided original data on BDNF concentration before and after applying a specific physical training protocol. The training modality included regular physiotherapy sessions [75,76,77], aerobic exercises [78,79,80], high-intensity interval training (HIIT) [81], and proprioceptive neuromuscular facilitation exercise (PNF) [82] (Details are illustrated in Table 3). In addition, the number of sessions varied among the included studies starting from only one session [78] to as many as 56 sessions [16]. Also, the duration of sessions ranged from 12 min [83] to 120 min [75]. 13 observational groups were included in the immediate analysis, and eleven observational groups were in the delayed analysis.

Sample collection immediately after physical training

Analysis for the immediate group showed a positive effect of physical training in general on BDNF level immediately after the intervention with (SMD [95%CI] = 0.49 [0.09 to 0.88]), p-value = 0.02, I2 = 85%, p-value < 0.001) (Fig. 7). Within the immediate group, we did a subgroup analysis on different training modalities. Eight observations that performed any sort of exercise fell into our exercise subgroup, and five observations applying regular rehabilitation or physiotherapy were categorized as rehabilitation subgroup. The subgroup analysis showed that only in the exercise group BDNF levels significantly increased immediately after physical training (SMD [95%CI] = 0.75 [0.25 to 1.25], p-value = 0.003). No subgroup differences were detected. Sensitivity analysis showed that the study of Anjum et al. [84] was influential (Additional file 12: Fig. S12). After omitting this record, the overall effect size did not remain significant (SMD [95%CI] = 0.34 [− 0.03 to 0.71], I2 = 82%) (Additional file 13: Fig. S13). Lastly, publication bias was not observed between the included studies (Fig. 8).

Fig. 7
figure 7

Forest immediate

Fig. 8
figure 8

Funnel immediate

Sample collection with a delay after physical training

The analysis of the delayed group consisting of eleven observations showed no significant effect of the intervention at this delayed phase of sample collection (SMD [95%CI] = 0.02 [− 0.43 to 0.47], I2 = 83%) (Fig. 9). Similarly, BDNF levels did not change significantly in any of the subgroups. Leave-one-out analysis showed that after omission of Wang et al., 2021 study [16], the I2 index reduced to 68% while the overall effect size remained not significant (Additional file 14: Fig. S14 and Additional file 15: Fig. S15). No publication bias in either group was noted (Fig. 10).

Fig. 9
figure 9

Forest delayed

Fig. 10
figure 10

Funnel delayed

Repeated transcranial magnetic stimulation (rTMS)

Four studies measured the BDNF levels in 105 PwS after receiving rTMS; Lu 2015 used plasma while the other three used serum samples [56, 75, 77, 85]. The overall meta-analysis of the studies revealed no difference in the BDNF levels between the rTMS and the sham stimulation group (SMD [95%CI] = 0.00 [− 0.27 to 0.27]). No significant heterogeneity was found (I2 = 0%, p-value = 0.48) (Fig. 11). Meta bias in the included studies is presented visually in the funnel plot (Fig. 12), with Begg’s and Egger’s tests of 0.0603 and 0.081, respectively.

Fig. 11
figure 11

rtms stroke corrected

Fig. 12
figure 12

Funnel rtms


With this study, we confirm that the BDNF level is significantly lower in the patients with stroke than in the healthy controls. Interestingly, it is also lower in patients with post-stroke depression compared to PwS without depression. These results are compatible with the hypothesis that a lower level of BDNF is associated with the pathogenesis of neural loss in several neuropsychiatric disorders and cognitive deficits [12, 86,87,88,89,90,91]. Although the severity and type of stroke, either ischemic or hemorrhagic, can possibly correlate with the BDNF level as addressed by Chaturvedi et al. [82], the lack of reporting data from the included studies prohibited us from further regression analysis of these influential factors.

We assume that neural rehabilitation following a stroke measured with BDNF happens in an insignificant amount in the absence of additional intervention. Individual differences in the neural recovery have made some fluctuations in the level of BDNF days, weeks and months post-stroke, but have led to no significant differences between various time points in this meta-analysis; the overall BDNF pattern was neither increasing nor decreasing through time. This implies that stroke can lead to an irreversible decrease in the level of BDNF or the rate of neural recovery.

In addition, our analysis also confirmed a positive effect of physical training, regardless of performing exercise or routine physiotherapy or rehabilitation, on the BDNF level immediately after the intervention. In contrast, no significant effect was detected when the BDNF samples were collected after a time point from the intervention (delayed). Moreover, the analysis of the effect of rTMS on PwS showed zero effect on the circulating BDNF.

BDNF protein is a member of nerve growth factors, discovered in 1982 [92]; since then, a strong body of evidence has suggested important roles of BDNF in neurogenesis and synaptic plasticity along with suppressive effects on apoptosis in the central and peripheral nervous system. BDNF works through different signaling mechanisms by binding to its high-affinity receptor, known as tropomyosin receptor kinase B (TrkB) [90, 93]. It appears that three main cascades are involved in BDNF signaling pathways; (1) Ras/MAPK/ERK pathway; (2) IRS-1/PI3K/AKT pathway, and (3) PLC/DAG/IP3 pathway. These pathways result in the regulation of the encoding of various proteins, which are associated with different processes such as neurogenesis, synaptic plasticity, and cell survival [90, 94,95,96]. All of which are essential for synaptogenesis, restoring the ability of recovery and survival after a neural insult such as stroke [97]. Circulating BDNF is detected and measured chiefly by ELISA kits; However, these kits demonstrate a reasonable difference in mean BDNF measures in the same samples; they differ in the number of mature vs pro BDNF detection. Among the existing kits, the Biosensis and Aviscera-Bioscience, measuring total BDNF and mature BDNF, respectively, are the most performant and recommended for clinical studies. Moreover, plasma samples are sensitive to preparation procedures such as room temperature and varying time needed for platelet lysis, making the pre-procedure time-consuming and leading to different reported measures with changing operators. Thus, it is advised to measure serum BDNF concentration minimally affected by extrinsic factors and about 100 folds higher than plasma levels [98].

Many studies have focused on the alternation of the peripheral BDNF level in different situations and reported BDNF changes in neurodegenerative disorders, brain insults, and psychiatric disorders [12, 89,90,91, 93]. Stroke as the second leading cause of death and morbidity worldwide is investigated remarkably, specifically in regards to post-stroke recovery measures. A notable number of studies have investigated the impact of numerous modalities such as oral or intravenous medications, physical interventions, and brain stimulation on the BDNF level as an indicator of plasticity in PwS. Within medications, rtPA, antioxidants such as Saffron, statins, and Cytoflavin, have shown promising effects on increasing the BDNF level in each individual study [39, 42, 52, 61], which did not meet the meta-analysis threshold in the current research article (total number of 3 studies). Additionally, specific brain stimulation using rTMS which was assessed by 4 independent studies showed zero effect on BDNF in our meta-analysis.

Post stroke depression (PSD)

The current study reveals decreased levels of BDNF among the PSD group compared to PwS with no clinical depression. This implies that a decreased BDNF level can be an early predictor of depression in PwS. Since the BDNF is also decreased generally in PwS, there should exist a definite criteria, either a threshold or a difference amount of drop in BDNF level, on which we consider a PwS susceptible to develop PSD. Suggested amount in the current literature are very wide and inconsistent for this matter. Yang et al. [44] mentioned a 28 fold higher risk of depression in PwS with BDNF levels lower than 5.86 ng/ml, while Li et al. [99] report an 11.5-fold increase in the risk of post-stroke depression in case of BDNF < 10.2 ng/ml. An increasing response to BDNF to antidepressant consumption in PwS diagnosed with PSD also suggests the effect of BDNF among this population [100, 101]. Altogether may open the door to the proposal of new therapeutic options in PwS.

Physical training

We confirm that exercises and rehabilitation programs promote BDNF production and motor recovery following stroke [102, 103]. Literature shows the impacts of training on post-stroke circulating BDNF levels vary based on the program’s duration and intensity [102, 104]. Programs with higher intensity resulted in higher BDNF levels as confirmed by de Morais et al., a significant increase in serum BDNF levels were detected in their moderate exercise group (64–76% of maximum heart rate), not their mild group (50–63% of maximum heart rate) [105]. Moreover, gradually increasing intensity results in a significantly higher increase in serum BDNF [102]. Similar to the exercise, the degree of the rehabilitation program correlated significantly with the BDNF level and motor recovery, supposing a critical threshold in the intensity that the impact could not be detected below that level [106]. As defined in mentioned studies, a threshold exists for the severity of the training that zero benefit is noticed below the point. This makes us assume that the duration of each session would have the same pattern of effect, which is awaiting to be discovered.

Although the duration of the training can potentially alter BDNF levels, none of our included studies has performed a specific, clear comparison for this matter (e.g., comparing the numbers of sessions or the session duration). In regards to comparing different exercise protocols with rehabilitation modalities, El-tamawy et al. suggest that implementing physiotherapy in combination with aerobic exercise leads to higher BDNF levels compared to the routine physiotherapy group [76]. Lastly, the effect of time points in data collection was of remarkable significance. Our analysis confirms a promising short-term effect of exercise on motor recovery by higher levels of circulatory BDNF when assessed immediately after the session, while low to zero long-term impact is detected on BDNF level following exercise. The problem is that the current protocols of treatment are failing to have a sustained effect and the termination of the intervention leads to a decrease in overall benefit. At this point, we need to come up with more effective treatment protocols for the physical training, and this does not imply that the exercise per se is ineffective; rather our existing modality is.


In conclusion, stroke significantly affects the level of BDNF, which is positively correlated with neural plasticity and post-stroke recovery in various domains such as cognition, affect, and motor function. Our study also confirms the significantly lower levels of BDNF in patients with stroke than the healthy controls, patients with the clinical diagnosis of depression to non-depressed patients and significantly higher levels of BDNF in patients who do moderate to severe physical training. Furthermore, literature imposes different modalities to overcome the effect of BDNF reduction, from which our study confirms the short-term effect of moderate to intense exercise or rehabilitation. We believe that BDNF could be regarded as a valuable diagnostic biomarker for acute stroke and a potential screening factor to observe the effectiveness of treatment. Existing modalities lack a definite protocol by which a maximum benefit is reached. Thus, further studies should focus on addressing the exact dosage of proposed drugs such as antioxidants, antidepressants, statins and a definite intensity and duration for the physical training. Lastly, investigating the role of BDNF supplementation for severe stroke patients could be of great value.

Availability of data and materials

The excel sheet for the extracted variables is available upon request.



Disability-adjusted life years


Patients with stroke


Brain-derived neurotrophic factor


Standard deviation


Standardized mean difference


Confidence interval


Repeated transcranial magnetic stimulation


Physical training


High-intensity interval training


Proprioceptive neuromuscular facilitation exercise


Post-stroke depression


  1. M Patrice Lindsay (Corresponding Author)1 BN, Ralph L. Sacco3, Michael Brainin4, Werner Hacke5, Sheila Martins6, Jeyaraj Pandian7, Valery Feigin. Global Stroke Fact Sheet 2019. World Stroke Organization (WSO). 2020:

  2. Feigin VL, Nichols E, Alam T, Bannick MS, Beghi E, Blake N, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–80.

    Article  Google Scholar 

  3. Pikula A, Beiser AS, Chen TC, Preis SR, Vorgias D, DeCarli C, et al. Serum brain-derived neurotrophic factor and vascular endothelial growth factor levels are associated with risk of stroke and vascular brain injury framingham study. Stroke. 2013;44(10):2768–75.

    Article  CAS  PubMed  Google Scholar 

  4. Li WY, Ling SC, Yang Y, Hu ZY, Davies H, Fang MR. Systematic hypothesis for post-stroke depression caused inflammation and neurotransmission and resultant on possible treatments. Neuroendocrinol Lett. 2014;35(2):104–9.

    PubMed  Google Scholar 

  5. Ploughman M, Eskes GA, Kelly LP, Kirkland MC, Devasahayam AJ, Wallack EM, et al. Synergistic benefits of combined aerobic and cognitive training on fluid intelligence and the role of IGF-1 in chronic stroke. Neurorehabil Neural Repair. 2019;33(3):199–212.

    Article  PubMed  Google Scholar 

  6. Huang EJ, Reichardt LF. Neurotrophins: roles in neuronal development and function. Annu Rev Neurosci. 2001;24(1):677–736.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Schinder AF, Poo M-M. The neurotrophin hypothesis for synaptic plasticity. Trends Neurosci. 2000;23(12):639–45.

    Article  CAS  PubMed  Google Scholar 

  8. Tadi P, Lui F. Acute Stroke. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.

  9. Diniz BS, Teixeira AL. Brain-derived neurotrophic factor and Alzheimer’s disease: physiopathology and beyond. NeuroMol Med. 2011;13(4):217–22.

    Article  CAS  Google Scholar 

  10. Ferreira RN, de Miranda AS, Rocha NP, Simoes e Silva AC, Teixeira AL, da Silva Camargos ER. Neurotrophic factors in Parkinson’s disease: what have we learned from pre-clinical and clinical studies? Curr Med Chem. 2018;25(31):3682–702.

    Article  CAS  PubMed  Google Scholar 

  11. Halepoto DM, Bashir S, Al-Ayadhi L. Possible role of brain-derived neurotrophic factor (BDNF) in autism spectrum disorder: current status. J Coll Phys Surg Pak. 2014;24(4):274–8.

    Google Scholar 

  12. Mojtabavi H, Saghazadeh A, van den Heuvel L, Bucker J, Rezaei N. Peripheral blood levels of brain-derived neurotrophic factor in patients with post-traumatic stress disorder (PTSD): A systematic review and meta-analysis. PLoS ONE. 2020;15(11):e0241928.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Hassan TM, Yarube IU. Peripheral brain-derived neurotrophic factor is reduced in stroke survivors with cognitive impairment. Pathophysiology. 2018;25(4):405–10.

    Article  CAS  PubMed  Google Scholar 

  14. Luo W, Liu T, Li S, Wen H, Zhou F, Zafonte R, et al. The serum BDNF level offers minimum predictive value for motor function recovery after stroke. Transl Stroke Res. 2019;10(4):342–51.

    Article  CAS  PubMed  Google Scholar 

  15. Stanne TM, Åberg ND, Nilsson S, Jood K, Blomstrand C, Andreasson U, et al. Low circulating acute brain-derived neurotrophic factor levels are associated with poor long-term functional outcome after ischemic stroke. Stroke. 2016;47(7):1943–5.

    Article  CAS  PubMed  Google Scholar 

  16. Wang H, Zhu C, Liu D, Wang Y, Zhang J, Wang S, et al. Rehabilitation training improves cognitive disorder after cerebrovascular accident by improving BDNF Bcl-2 and Bax expressions in regulating the JMK pathway. Eur Rev Med Pharmacol Sci. 2021;25(10):3807–21.

    PubMed  Google Scholar 

  17. Graph reader.

  18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529–36.

    Article  PubMed  Google Scholar 

  19. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006;11(2):193–206.

    Article  PubMed  Google Scholar 

  20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  CAS  PubMed  Google Scholar 

  21. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. 2010;1(2):97–111.

    Article  PubMed  Google Scholar 

  22. Li B, Piao CS, Liu XY, Guo WP, Xue YQ, Duan WM, et al. Brain self-protection: The role of endogenous neural progenitor cells in adult brain after cerebral cortical ischemia. Brain Res. 2010;1327:91–102.

    Article  CAS  PubMed  Google Scholar 

  23. Reynolds MA, Kirchick HJ, Dahlen JR, Anderberg JM, McPherson PH, Nakamura KK, et al. Early biomarkers of stroke. Clin Chem. 2003;49(10):1733–9.

    Article  CAS  PubMed  Google Scholar 

  24. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

    Article  CAS  PubMed  Google Scholar 

  26. Kostenko EV. Influence chronopharmacology therapy methionine (Melaxen) on the dynamics of sleep disturbance, cognitive and emotional disorders, brain-derived neurotrophic factor (BDNF) in patients with cerebral stroke in the early and late recovery periods. Zhurnal Nevrologii i Psihiatrii imeni SS Korsakova. 2017;117(3):56–64.

    Article  CAS  Google Scholar 

  27. Tokami H, Ago T, Sugimori H, Kuroda J, Awano H, Suzuki K, et al. RANTES has a potential to play a neuroprotective role in an autocrine/paracrine manner after ischemic stroke. Brain Res. 2013;1517:122–32.

    Article  CAS  PubMed  Google Scholar 

  28. Boyne P, Meyrose C, Westover J, Whitesel D, Hatter K, Reisman DS, et al. Exercise intensity affects acute neurotrophic and neurophysiological responses poststroke. J Appl Physiol. 2019;126(2):431–43.

    Article  CAS  PubMed  Google Scholar 

  29. Cichon N, Bijak M, Czarny P, Miller E, Synowiec E, Sliwinski T, et al. Increase in blood levels of growth factors involved in the neuroplasticity process by using an extremely low frequency electromagnetic field in post-stroke patients. Front Aging Neurosci. 2018;10:9.

    Article  Google Scholar 

  30. Casas S, Perez AF, Mattiazzi M, Lopez J, Folgueira A, Gargiulo-Monachelli GM, et al. Potential biomarkers with plasma cortisol, brain-derived neurotrophic factor and nitrites in patients with acute ischemic stroke. Curr Neurovasc Res. 2017;14(4):338–46.

    Article  CAS  PubMed  Google Scholar 

  31. Jiménez I, Sobrino T, Brea D, Cristobo I, Rodríguez-Yáñez M, Blanco M, et al. Molecular markers of inflammation in post-stroke depression. Trauma. 2008;19(2):113–9.

    Google Scholar 

  32. Di Lazzaro V, Profice R, Pilato F, Dileone M, Florio L, Tonali PA, et al. BDNF plasma levels in acute stroke. Neurosci Lett. 2007;422(2):128–30.

    Article  PubMed  Google Scholar 

  33. Greisenegger S, Segal HC, Burgess AI, Poole DL, Mehta Z, Rothwell PM. Biomarkers and mortality after transient ischemic attack and minor ischemic stroke population-based study. Stroke. 2015;46(3):659–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hidayat A, Arief M, Wijaya A, As’ad S. Vascular endothelial growth factor and brain-derived neurotrophic factor levels in ischemic stroke subject. Indonesian Biomed J. 2016;8(2):115–8.

    Article  Google Scholar 

  35. Kotlega D, Zembron-Lacny A, Morawin B, Golab-Janowska M, Nowacki P, Szczuko M. Free fatty acids and their inflammatory derivatives affect BDNF in stroke patients. Mediat Inflam. 2020;2020:89.

    Article  Google Scholar 

  36. Kozak HH, Uguz F, Kilinc I, Uca AU, Tokgoz OS, Akpinar Z, et al. Delirium in patients with acute ischemic stroke admitted to the non-intensive stroke unit: Incidence and association between clinical features and inflammatory markers. Neurol Neurochir Pol. 2017;51(1):38–44.

    Article  PubMed  Google Scholar 

  37. Lasek-Bal A, Jedrzejowska-Szypulka H, Rozycka J, Bal W, Holecki M, Dulawa J, et al. Low Concentration of BDNF in the acute phase of ischemic stroke as a factor in poor prognosis in terms of functional status of patients. Med Sci Monit. 2015;21:3900–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Lasek-Bal A, Jedrzejowska-Szypulka H, Student S, Warsz-Wianecka A, Zareba K, Puz P, et al. The importance of selected markers of inflammation and blood-brain barrier damage for short-term ischemic stroke prognosis. J Physiol Pharmacol. 2019;70(2):209–17.

    Google Scholar 

  39. Rodier M, Quirie A, Prigent-Tessier A, Bejot Y, Jacquin A, Mossiat C, et al. Relevance of Post-Stroke Circulating BDNF Levels as a Prognostic Biomarker of Stroke Outcome. Impact of rt-PA Treatment. PLoS ONE. 2015;10:10.

    Article  Google Scholar 

  40. Siotto M, Aprile I, Simonelli I, Pazzaglia C, Ventriglia M, Santoro M, et al. An exploratory study of BDNF and oxidative stress marker alterations in subacute and chronic stroke patients affected by neuropathic pain. J Neural Transm. 2017;124(12):1557–66.

    Article  CAS  PubMed  Google Scholar 

  41. Widodo J, Asadul A, Wijaya A, Lawrence G. Correlation between Nerve Growth Factor (NGF) with Brain Derived Neurotropic Factor (BDNF) in Ischemic Stroke Patient. Bali Medical Journal. 2016;5(2):10–3.

    Article  Google Scholar 

  42. Zhang JM, Mu XL, Breker DA, Li Y, Gao ZL, Huang YL. Atorvastatin treatment is associated with increased BDNF level and improved functional recovery after atherothrombotic stroke. Int J Neurosci. 2017;127(1):92–7.

    Article  CAS  PubMed  Google Scholar 

  43. Zhou Z, Lu T, Xu G, Yue X, Zhu W, Ma M, et al. Decreased serum brain-derived neurotrophic factor (BDNF) is associated with post-stroke depression but not with BDNF gene Val66Met polymorphism. Clin Chem Lab Med. 2011;49(2):185–9.

    Article  CAS  PubMed  Google Scholar 

  44. Yang L, Zhang Z, Sun D, Xu Z, Yuan Y, Zhang X, et al. Low serum BDNF may indicate the development of PSD in patients with acute ischemic stroke. Int J Geriatr Psychiatry. 2011;26(5):495–502.

    Article  PubMed  Google Scholar 

  45. Wang J, Huang Q, Ding J, Wang X. Elevated serum levels of brain-derived neurotrophic factor and miR-124 in acute ischemic stroke patients and the molecular mechanism. Biotech. 2019;9(11):1–6.

    Google Scholar 

  46. Wang J, Gao L, Yang YL, Li YQ, Chang T, Man MH, et al. Low serum levels of brain-derived neurotrophic factor were associated with poor short-term functional outcome and mortality in acute ischemic stroke. Mol Neurobiol. 2017;54(9):7335–42.

    Article  CAS  PubMed  Google Scholar 

  47. Stanne TM, Aberg ND, Nilsson S, Jood K, Blomstrand C, Andreasson U, et al. Low circulating acute brain-derived neurotrophic factor levels are associated with poor long-term functional outcome after ischemic stroke. Stroke. 2016;47(7):1943–5.

    Article  CAS  PubMed  Google Scholar 

  48. Santos GL, Alcântara CC, Silva-Couto MA, García-Salazar LF, Russo TL. Decreased brain-derived neurotrophic factor serum concentrations in chronic post-stroke subjects. J Stroke Cerebrovasc Dis. 2016;25(12):2968–74.

    Article  PubMed  Google Scholar 

  49. Qiao H-J, Li Z-Z, Wang L-M, Sun W, Yu J-C, Wang B. Association of lower serum Brain-derived neurotrophic factor levels with larger infarct volumes in acute ischemic stroke. J Neuroimmunol. 2017;307:69–73.

    Article  CAS  PubMed  Google Scholar 

  50. Pascotini ET, Flores AE, Kegler A, Konzen V, Fornari AL, Arend J, et al. Brain-derived neurotrophic factor levels are lower in chronic stroke patients: a relation with manganese-dependent superoxide dismutase ALA16VAL single nucleotide polymorphism through tumor necrosis factor-alpha and caspases pathways. J Stroke Cerebrovasc Dis. 2018;27(11):3020–9.

    Article  PubMed  Google Scholar 

  51. Koroleva E, Alifirova V, Latypova A, Ivanova S, Levchuk L, Kazakov S. Correlation between neurological deficit and serum BDNF in patients with ischemic stroke after early rehabilitation. Eur J Neurol. 2019;26:394.

    Google Scholar 

  52. Karakulova YV, Selyanina NV, Zhelnin AV, Filimonova TA, Tsepilov SV. Effects of antioxidant treatment on neurotrophins and rehabilitation processes following stroke. Neurosci Behav Physiol. 2018;48(1):54–7.

    Article  CAS  Google Scholar 

  53. Huțanu A, Iancu M, Maier S, Bălaşa R, Dobreanu M. Plasma biomarkers as potential predictors of functional dependence in daily life activities after ischemic stroke: a single center study. Ann Indian Acad Neurol. 2020;23(4):496.

    PubMed  Google Scholar 

  54. Chan A, Yan J, Csurhes P, Greer J, McCombe P. Circulating brain derived neurotrophic factor (BDNF) and frequency of BDNF positive T cells in peripheral blood in human ischemic stroke: effect on outcome. J Neuroimmunol. 2015;286:42–7.

    Article  CAS  PubMed  Google Scholar 

  55. Algin A, Erdogan MO, Aydin I, Poyraz MK, Sirik M. Clinical usefulness of brain-derived neurotrophic factor and visinin-like protein-1 in early diagnostic tests for acute stroke. Am J Emerg Med. 2019;98:56.

    Google Scholar 

  56. Lu HT, Zhang T, Wen M, Sun L. Impact of repetitive transcranial magnetic stimulation on post-stroke dysmnesia and the role of BDNF Val66Met SNP. Med Sci Monit. 2015;21:761–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Chen HG, Wang M, Jiao AH, Tang G, Zhu W, Zou P, et al. Research on changes in cognitive function, beta-amyloid peptide and neurotrophic factor in stroke patients. Eur Rev Med Pharmacol Sci. 2018;22(19):6448–55.

    PubMed  Google Scholar 

  58. Algin A, Erdogan MO, Aydin I, Poyraz MK, Sirik M. Clinical usefulness of brain-dern-like protein-1 in early diagnostic tests for acute stroke. Am J Emerg Med. 2019;37(11):2051–4.

    Article  PubMed  Google Scholar 

  59. Hutanu A, Iancu M, Maier S, Balasa R, Dobreanu M. Plasma biomarkers as potential predictors of functional dependence in daily life activities after ischemic stroke: a single center study. Ann Indian Acad Neurol. 2020;23(4):496–503.

    PubMed  Google Scholar 

  60. Pedarci M, Breniere C, Perne N, Vergely C, Bejot Y, Marie C. Brain-derived neurotrophic factor in peripheral blood mononuclear cells and stroke outcome. Exp Biol Med. 2018;243(15–16):1207–11.

    Google Scholar 

  61. Asadollahi M, Nikdokht P, Hatef B, Sadr SS, Sahraei H, Assarzadegan F, et al. Protective properties of the aqueous extract of saffron (Crocus sativus L.) in ischemic stroke, randomized clinical trial. J Ethnopharmacol. 2019;238:8.

    Article  Google Scholar 

  62. Mourao AM, Vicente LCC, Abreu MNS, Sant’Anna RV, Vieira ELM, de Souza LC, et al. Plasma levels of brain-derived neurotrophic factor are associated with prognosis in the acute phase of ischemic stroke. J Stroke Cerebrovasc Dis. 2019;28(3):735–40.

    Article  PubMed  Google Scholar 

  63. Otero-Ortega L, Gutierrez-Fernandez M, Gutierrez-Zuniga R, Madero-Jarabo R, de Lecinana MA, Laso-Garcia F, et al. The effect of post-stroke hyperglycaemia on the levels of brain damage and repair-related circulating biomarkers: the Glycaemia in Acute Stroke Study II. Eur J Neurol. 2019;26(12):1439–46.

    Article  CAS  PubMed  Google Scholar 

  64. Billinger SA, Sisante JFV, Whitaker AA, Abraham MG. Time course of flow-mediated dilation and vascular endothelial growth factor following acute stroke. J Stroke Cerebrovasc Dis. 2018;27(4):957–62.

    Article  PubMed  Google Scholar 

  65. Lopez-Cancio E, Ricciardi AC, Sobrino T, Cortes J, de la Ossa NP, Millan M, et al. Reported prestroke physical activity is associated with vascular endothelial growth factor expression and good outcomes after stroke. J Stroke Cerebrovasc Dis. 2017;26(2):425–30.

    Article  PubMed  Google Scholar 

  66. Roslavtceva V, Bushmelev E, Astanin P, Zabrodskaya T, Salmina A, Prokopenko S, et al. Blood plasma trophic growth factors predict the outcome in patients with acute ischemic stroke. 2020. p. 27–39.

  67. Sobrino T, Rodriguez-Yanez M, Campos F, Iglesias-Rey R, Millan M, de la Ossa NP, et al. Association of high serum levels of growth factors with good outcome in ischemic stroke: a multicenter study. Transl Stroke Res. 2020;11(4):653–63.

    Article  CAS  PubMed  Google Scholar 

  68. Bembenek JP, Kurczych K, Klysz B, Cudna A, Antczak J, Czlonkowska A. Prediction of recovery and outcome using motor evoked potentials and brain derived neurotrophic factor in subacute stroke. J Stroke Cerebrovasc Dis. 2020;29:11.

    Article  Google Scholar 

  69. Bintang AK, Akbar M, Amran MY, Hammado N. The effect of high-and low-frequency repetitive transcranial magnetic stimulation therapy on serum brain-derived neurotropic factor level and motor ability in ischemic stroke patients: A single-center study. Open Access Macedonian J Med Sci. 2020;8(2):198–204.

    Article  Google Scholar 

  70. Prodjohardjono A, Sutarni S, Setyopranoto I. Serum Brain-Derived Neurotrophic Factor (BDNF) Level May Predict the Functional Outcome of Acute Ischemic Stroke Patients. Biomed Pharmacol J. 2020;13:1963.

    Article  Google Scholar 

  71. Han ZX, Wang Y, Qi LL, Wang JN, Wong O, Chen JH, et al. Differential Association of Serum BDNF with poststroke depression and poststroke anxiety. Arch Phys Med Rehabil. 2020;101(8):1355–66.

    Article  PubMed  Google Scholar 

  72. Kozak HH, Uguz F, Kilinc I, Uca AU, Tokgoz OS, Guney F, et al. A cross-sectional study to assess the association between major depression and inflammatory markers in patients with acute ischemic stroke. Indian J Psychiatry. 2019;61(3):283–9.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Li J, Zhao YD, Zeng JW, Chen XY, Wang RD, Cheng SY. Serum Brain-derived neurotrophic factor levels in post-stroke depression. J Affect Disord. 2014;168:373–9.

    Article  CAS  PubMed  Google Scholar 

  74. Syafrita Y, Amir D, Susanti R, Fadhilah I. Relationship of brain-derived neurotrophic factor, malondialdehyde, and 8-hydroxy 2-deoxyguanosine with post-ischemic stroke depression. Dementia e Neuropsychologia. 2020;14(1):41–6.

    Article  Google Scholar 

  75. Chang WH, Shin MA, Lee A, Kim H, Kim YH. Relationship between Serum BDNF Levels and Depressive Mood in Subacute Stroke Patients: A Preliminary Study. Int J Mol Sci. 2018;19:10.

    Article  Google Scholar 

  76. El-Tamawy MS, Abd-Allah F, Ahmed SM, Darwish MH, Khalifa HA. Aerobic exercises enhance cognitive functions and brain derived neurotrophic factor in ischemic stroke patients. NeuroRehabilitation. 2014;34(1):209–13.

    Article  PubMed  Google Scholar 

  77. Mirowska-Guzel D, Gromadzka G, Seniow J, Lesniak M, Bilik M, Waldowski K, et al. Association between BDNF-196 G > A and BDNF-270 C > T polymorphisms, BDNF concentration, and rTMS-supported long-term rehabilitation outcome after ischemic stroke. NeuroRehabilitation. 2013;32(3):573–82.

    Article  PubMed  Google Scholar 

  78. Kim TG, Bae SH, Kim KY. Effects of dual-task training with different intensity of aerobic exercise on cognitive function and neurotrophic factors in chronic stroke patients. Res J Pharm Technol. 2019;12(2):693–8.

    Article  Google Scholar 

  79. Ryan AS, Xu HC, Ivey FM, Macko RF, Hafer-Macko CE. Brain-derived neurotrophic factor, epigenetics in stroke skeletal muscle, and exercise training. Neurol-Genetics. 2019;5:3.

    Article  Google Scholar 

  80. Silva M, Morais V, Santos R, Rocha N, Christo P, Fuscaldi L, et al. No change in brain-derived neurotrophic factor levels following a single session of light to-moderate intensity walk in chronic stroke patients. J Neurol Dis. 2017;05:2.

    Google Scholar 

  81. Hsu CC, Fu TC, Huang SC, Chen CPC, Wang JS. Increased serum brain-derived neurotrophic factor with high-intensity interval training in stroke patients: A randomized controlled trial. Ann Phys Rehab Med. 2020;64:101345.

    Google Scholar 

  82. Chaturvedi P, Singh AK, Tiwari V, Thacker AK. Post-stroke BDNF concentration changes following proprioceptive neuromuscular facilitation (PNF) exercises. J Fam Med Primary Care. 2020;9(7):3361–9.

    Article  Google Scholar 

  83. Bastawy S, Ahmed AM. The role of serum levels of insulin-like growth factor-1 and brain-derived neurotrophic factor in predicting recovery in stroke. Egyp J Hosp Med. 2019;76(1):3170–5.

    Article  Google Scholar 

  84. Anjum AF, Khan HF, Sadiq N, Samad A, Jawwad G, Ayaz H. Effects of virtual rehabilitation and constraint induced movement therapy on brain derived neurotrophic factor mediated motor improvement in stroke patients. J Bahria Univ Med Dent Coll. 2020;10(1):30–4.

    Article  Google Scholar 

  85. Niimi M, Hashimoto K, Kakuda W, Miyano S, Momosaki R, Ishima T, et al. Role of brain-derived neurotrophic factor in beneficial effects of repetitive transcranial magnetic stimulation for upper limb hemiparesis after stroke. PLoS ONE. 2016;11:3.

    Article  Google Scholar 

  86. Dell’Osso L, Carmassi C, Del Debbio A, Dell’Osso MC, Bianchi C, Da Pozzo E, et al. Brain-derived neurotrophic factor plasma levels in patients suffering from post-traumatic stress disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(5):899–902.

    Article  CAS  PubMed  Google Scholar 

  87. Giacobbo BL, Doorduin J, Klein HC, Dierckx RA, Bromberg E, de Vries EF. Brain-derived neurotrophic factor in brain disorders: focus on neuroinflammation. Mol Neurobiol. 2019;56(5):3295–312.

    Article  Google Scholar 

  88. Rahmani F, Saghazadeh A, Rahmani M, Teixeira AL, Rezaei N, Aghamollaii V, et al. Plasma levels of brain-derived neurotrophic factor in patients with Parkinson disease: a systematic review and meta-analysis. Brain Res. 2019;1704:127–36.

    Article  CAS  PubMed  Google Scholar 

  89. Saghazadeh A, Rezaei N. Brain-derived neurotrophic factor levels in autism: a systematic review and meta-analysis. J Autism Develop Disord. 2017;47:4.

    Article  Google Scholar 

  90. Bathina S, Das UN. Brain-derived neurotrophic factor and its clinical implications. Arch Med Sci. 2015;11(6):1164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Karantali E, Kazis D, Papavasileiou V, Prevezianou A, Chatzikonstantinou S, Petridis F, et al. Serum BDNF levels in acute stroke: a systematic review and meta-analysis. Medicina. 2021;57(3):297.

    Article  PubMed  PubMed Central  Google Scholar 

  92. Barde Y-A, Edgar D, Thoenen H. Purification of a new neurotrophic factor from mammalian brain. EMBO J. 1982;1(5):549–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Binder DK, Scharfman HE. Brain-derived neurotrophic factor. Growth Factors (Chur, Switzerland). 2004;22(3):123.

    Article  CAS  Google Scholar 

  94. Dimitropoulou A, Bixby JL. Regulation of retinal neurite growth by alterations in MAPK/ERK kinase (MEK) activity. Brain Res. 2000;858(1):205–14.

    Article  CAS  PubMed  Google Scholar 

  95. Pezet S, Malcangio M, McMahon SB. BDNF: a neuromodulator in nociceptive pathways? Brain Res Rev. 2002;40(1–3):240–9.

    Article  CAS  PubMed  Google Scholar 

  96. Vaillant A, Mazzoni I, Tudan C, Boudreau M, Kaplan D, Miller F. Depolarization and neurotrophins converge on the phosphatidylinositol 3-kinase–Akt pathway to synergistically regulate neuronal survival. J Cell Biol. 1999;146(5):955–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Wlodarczyk L, Szelenberger R, Cichon N, Saluk-Bijak J, Bijak M, Miller E. Biomarkers of angiogenesis and neuroplasticity as promising clinical tools for stroke recovery evaluation. Int J Mol Sci. 2021;22(8):3949.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  98. Polacchini A, Metelli G, Francavilla R, Baj G, Florean M, Mascaretti LG, et al. A method for reproducible measurements of serum BDNF: comparison of the performance of six commercial assays. Sci Rep. 2015;5(1):17989.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Li J, Zhao Y-D, Zeng J-W, Chen X-Y, Wang R-D. Serum Brain-derived neurotrophic factor levels in post-stroke depression. Stroke. 2014;168:373–9.

    CAS  Google Scholar 

  100. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008;64(6):527–32.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Shimizu E, Hashimoto K, Okamura N, Koike K, Komatsu N, Kumakiri C, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54(1):70–5.

    Article  CAS  PubMed  Google Scholar 

  102. Sun J, Ke Z, Yip SP, Hu XL, Zheng XX, Tong KY. Gradually increased training intensity benefits rehabilitation outcome after stroke by BDNF upregulation and stress suppression. Biomed Res Int. 2014;2014:9.

    Article  Google Scholar 

  103. Ploughman M, Windle V, MacLellan CL, White N, Dore JJ, Corbett D. Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke. 2009;40(4):1490–5.

    Article  CAS  PubMed  Google Scholar 

  104. Alcantara CC, Garcia-Salazar LF, Silva-Couto MA, Santos GL, Reisman DS, Russo TL. Post-stroke BDNF concentration changes following physical exercise: a systematic review. Front Neurol. 2018;9:34.

    Article  Google Scholar 

  105. de Morais VAC, Tourino MFD, Almeida ACD, Albuquerque TBD, Linhares RC, Christo PP, et al. A single session of moderate intensity walking increases brain-derived neurotrophic factor (BDNF) in the chronic post-stroke patients. Top Stroke Rehabil. 2018;25(1):1–5.

    Article  PubMed  Google Scholar 

  106. MacLellan CL, Keough MB, Granter-Button S, Chernenko GA, Butt S, Corbett D. A critical threshold of rehabilitation involving brain-derived neurotrophic factor is required for poststroke recovery. Neurorehabil Neural Repair. 2011;25(8):740–8.

    Article  PubMed  Google Scholar 

Download references


We acknowledge all the authors who generously shared their raw data with us.


No funding was used to conduct the present study.

Author information

Authors and Affiliations



HM: ideation, protocol creation, search strategy, initial search, screening, data extraction, analyzing, manuscript preparation, submission. ZSh: initial search, screening, data extraction, manuscript preparation. SM: analyzing, manuscript preparation, proofread. AA: screening, data extraction, manuscript preparation. NR: ideation, supervision, proofread. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Nima Rezaei.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file1

: Figure 1. Influence analysis plot of BDNF levels among PwS vs Healthy controls. The study of Algin et al. 2019 was found influential.

Additional file 2

: Figure 2. Meta-analysis of the BDNF levels in PwS, Baseline vs Day 1. We found no significant difference between the two groups.

Additional file 3

: Figure 3. Meta-analysis of the BDNF levels in PwS, Day 1 vs Week 1. We found no significant difference between the two groups.

Additional file 4

: Figure 4. Meta-analysis of the BDNF levels in PwS, Baseline vs Over 1 month. We found no significant difference between the two groups.

Additional file 5

: Figure 5. Meta-analysis of the BDNF levels in PwS, Baseline vs Week 1. We found no significant difference between the two groups.

Additional file 6

: Figure 6. Meta-analysis of the BDNF levels in PwS, Week 1 vs Over 1 month. We found no significant difference between the two groups.

Additional file 7

: Figure 7. Funnel plot of the studies included in Baseline vs Day 1.

Additional file 8

: Figure 8. Funnel plot of the studies included in Day 1 vs Week 1.

Additional file 9

: Figure 9. Funnel plot of the studies included in Baseline vs Over 1 month.

Additional file 10

: Figure 10. Funnel plot of the studies included in Baseline vs Week 1.

Additional file 11

: Figure 11. Funnel plot of the studies included in Week 1 vs Over 1 month.

Additional file 12

: Figure 12. Influence analysis plot of BDNF levels in physical training subgroup baseline vs. immediate after the training. The study of Anjum et al. 2020 was found influential.

Additional file 13

: Figure 13. Influence analysis, ‘leave one out’ plot, of BDNF levels in physical training subgroup baseline vs. immediate after the training. Omitting the study of Anjum et al. 2020 resulted in a non-significant difference between the two groups.

Additional file 14

: Figure 14. Influence analysis plot of BDNF levels in physical training subgroup baseline vs. with a delayed period after the training. No influential study was found.

Additional file 15

: Figure 15. Influence analysis, ‘leave one out’ plot, of BDNF levels in physical training subgroup baseline vs. with a delayed period after the training. After omitting the study of Wang et al. 2021 the I2 index reduced to 68%.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mojtabavi, H., Shaka, Z., Momtazmanesh, S. et al. Circulating brain-derived neurotrophic factor as a potential biomarker in stroke: a systematic review and meta-analysis. J Transl Med 20, 126 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: